Skip to Main Content

Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot?

Share the news with us, and we’ll share it with others. That’s right. Send us your changes, and we’ll find a home for them. Don’t be shy. Everyone wants to know who is coming and going, especially with all the ongoing layoffs. Despite the downsizing, there is movement. Here are some of the latest comings and goings. Recognize anyone?

And here is our regular feature in which we highlight a different person each week. This time around, we note that Decibel Therapeutics hired Steven Holtzman as chief executive officer and president. Previously, he was executive vice president, corporate development at Biogen. He was also a founder and chief executive officer at Infinity Pharmaceuticals and chief business officer at Millennium Pharmaceuticals.


Juniper Pharmaceuticals hired Alicia Secor as chief executive and president;

Astellas hired Joseph Devaney as vice president, government affairs and policy;


Amicus Therapeutics hired Andrew Mulberg as vice president, regulatory strategy;

Advaxis hired Ranya Dajani as vice president, corporate development;

Astellas promoted John Demaree to vice president of oncology marketing in the Americas region;

AMAG Pharmaceuticals hired Mark Stanton as vice president, market access and corporate accounts;

Flagship Ventures hired former Merck chief medical officer Michael Rosenblatt as chief medical officer;

Rexahn Pharmaceuticals hired Lisa Nolan as chief business officer;

Parexel said that Ingo Bank resigned as chief financial officer;

Boston Pharmaceuticals hired Ian Sanderson as chief financial officer;

Biostage hired Harout DerSimonian as chief scientific officer;

Iroko Pharmaceuticals named Louis Vollmer as chief executive officer;

WAVE Life Sciences hired Dr. Michael Panzara as head of its neurology franchise;

Second Genome hired Glenn Nedwin as chief executive officer and president;

Calimmune hired Tana Session as vice president, human resources;

Calimmune promoted Jeffrey Bartlett to chief scientific officer;

Albireo hired Thomas Shea as chief financial officer.